Our previous studies reported that the clinical implications of serum and exosomal LDHC gene (a CTA molecule) expressions in BC and HCC, serving as an assistant for diagnosis, efficacy evaluation, and recurrence monitoring [23, 24]. Here, LDHC is linked to breast cancer.